Value of PCR as a de-escalation tool for an Antimicrobial Stewardship Program at a Community-based hospital

Wilbert Fuerte
_Homestead Hospital_, WilbertF@baptisthealth.net

Jorge Mejia
_Baptist Health South Florida_, JorgeMe@baptisthealth.net

Winifred Pardo
_Homestead Hospital_, wpardo@baptisthealth.net

Patricia Yulkowski
_Baptist Health South Florida_, PatriciaY@baptisthealth.net

Silvia Costales
_Homestead Hospital_, SilviaCo@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

_Citation_
Fuerte, Wilbert; Mejia, Jorge; Pardo, Winifred; Yulkowski, Patricia; and Costales, Silvia, "Value of PCR as a de-escalation tool for an Antimicrobial Stewardship Program at a Community-based hospital" (2019). _All Publications_. 3306.
https://scholarlycommons.baptisthealth.net/se-all-publications/3306

This Conference Poster – Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.
Value of PCR as a de-escalation tool for an Antimicrobial Stewardship Program at a community-based hospital

Wilbert J. Fuerte, Pharm.D., BCIDP, Jorge Mejia, MD, Winifred Pardo, Pharm.D., BCPS, Patricia Yulkowski BSN, Silvia Costales BSMT
Homestead Hospital, Homestead, Florida

### Background

- On January 29th, 2016, the facility acquired the FilmArray Respiratory Panel (BioFire) TM Diagnostics, Inc. the first multiplex polymerase chain reaction (PCR) molecular panel approved by the FDA for the detection of both bacterial and viral respiratory pathogens.
- Sensitivity and specificity of this technology has been reported as 80-100%, and 100%, respectively, allowing for an optimal approach in the diagnosis of influenza and other organisms.
- An essential element of an Antimicrobial Stewardship Program (ASP) as outlined by the CDC and Joint Commission is to perform a “48-hour timeout” to assess the patient for opportunities, including de-escalation and discontinuation of antimicrobials.
- At our facility, we identified the need to review patients prescribed oseltamivir and any associated antibiotics for ASP opportunities. With the PCR tool available pharmacists were educated through an associated workflow to contact prescribers (within 48 hours) for de-escalation of oseltamivir when results were negative for influenza. For influenza positive patients who were also prescribed antibiotics, a procalcitonin level was recommended, and if appropriate, antibiotic de-escalation was suggested. Additionally, pharmacists notified nursing to initiate or discontinue droplet isolation based on the PCR influenza results.

### Objectives

1. To evaluate the effectiveness of pharmacist interventions utilizing PCR results for patients receiving oseltamivir and concurrent antibiotics
2. To determine intervention results by pharmacists with regards to isolation requirements.
3. Calculate potential cost-savings based on intervention data.

### Methods

- This study was determined to be exempt by Baptist Health South Florida Institutional Review Board.
- Single-center, retrospective chart review.
- Inclusion Criteria:
  - Patients 18 years of age and older.
  - Receiving oseltamivir with an associated pharmacist intervention documented.
- Exclusion Criteria:
  - Patients younger than 18 years of age
  - Receiving oseltamivir with no associated documented intervention.
- List generated for patients receiving oseltamivir with an associated ASP intervention documented was obtained from a data analytics platform.
- Charts were reviewed for PCR results, pharmacist intervention data, procalcitonin levels, and 30-day readmission rate.
- Group purchasing organization (GPO) pricing of antimicrobials was utilized for estimated cost-savings.
- Pharmacist Workflow:

### Results

<table>
<thead>
<tr>
<th>Negative Influenza PCR (n = 38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient discontinued</td>
</tr>
<tr>
<td>Outpatient continued</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Positive Influenza PCR (n = 36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients receiving oseltamivir/PCV antibodies</td>
</tr>
<tr>
<td>Antibiotics discontinued (negative procalcitonin)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Droplet Isolation (n = 74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isolated</td>
</tr>
<tr>
<td>Discontinued</td>
</tr>
</tbody>
</table>

### Limitations

- Only patients for whom an ASP intervention was documented were included in this project.
- Patients with negative PCR and associated antibiotics were not reviewed.
- 30-day readmission was only assessed within the Baptist Health South Florida (BHSF) system.

### Conclusion

- Pharmacist interventions for negative PCR showed a 71% (27/38) success rate in discontinuation of oseltamivir within 48 hours.
- Successful antibiotic discontinuation for patients with a positive PCR result and normal procalcitonin was 63% (12/19).
- Pharmacy identified 14.9% (11/74) of patients who required initiation of droplet isolation, and 20.3% (15/74) who did not need it.
- Overall, we estimated a total cost-saving of $4,057.83 during the study period as a result of pharmacist-driven ASP interventions.

### References


### Disclosure

- Authors of this project have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.